Literature DB >> 17468045

Animal models of restless legs syndrome.

W G Ondo1, H R Zhao, W D Le.   

Abstract

Restless legs syndrome (RLS) is a common disease with prevalence up to 10% in the general population. It is mostly a subjective condition, making animal models intrinsically difficult. General increased activity (urge to move) and limb movements consistent with periodic limb movements of sleep, seen in most patients with RLS, are currently our best behavioral markers. Our best understanding of human RLS demonstrates reduced central nervous system (CNS) iron stores and dysfunction of dopaminergic systems, which most likely involves the spinal cord. Based upon this knowledge, animal manipulations, including destruction of the A11 diencephalic-spinal tract and iron deprivation, have resulted in animal behavior consistent with RLS. Dopamine receptor type 3 knockout mice also show general increased activity. Pharmacologic blockade of dopamine receptors in rodents has also caused movements resembling periodic limb movements of sleep in older rodents but not in younger animals. More sophisticated animal modeling is needed to facilitate our understanding of RLS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468045     DOI: 10.1016/j.sleep.2007.03.010

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  14 in total

Review 1.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

Review 2.  Sleep-Wake Disorders in Stroke-Increased Stroke Risk and Deteriorated Recovery? An Evaluation on the Necessity for Prevention and Treatment.

Authors:  Simone B Duss; Anne-Kathrin Brill; Panagiotis Bargiotas; Laura Facchin; Filip Alexiev; Mauro Manconi; Claudio L Bassetti
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-07       Impact factor: 5.081

3.  Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children.

Authors:  Geoffrey Rulong; Thomas Dye; Narong Simakajornboon
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 4.  Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.

Authors:  Christopher J Earley; George R Uhl; Stefan Clemens; Sergi Ferré
Journal:  Sleep Med       Date:  2016-06-27       Impact factor: 3.492

5.  Restless legs syndrome is frequent in narcolepsy with cataplexy patients.

Authors:  Giuseppe Plazzi; Raffaele Ferri; Elena Antelmi; Sophie Bayard; Christian Franceschini; Filomena I I Cosentino; Beatriz Abril; Karen Spruyt; Federica Provini; Pasquale Montagna; Yves Dauvilliers
Journal:  Sleep       Date:  2010-05       Impact factor: 5.849

Review 6.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

7.  Netrin-DCC, Robo-Slit, and heparan sulfate proteoglycans coordinate lateral positioning of longitudinal dopaminergic diencephalospinal axons.

Authors:  Edda Kastenhuber; Ursula Kern; Joshua L Bonkowsky; Chi-Bin Chien; Wolfgang Driever; Joern Schweitzer
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

8.  Evidence of increased restless legs syndrome occurrence in chronic and highly disabling migraine.

Authors:  Cinzia Lucchesi; Enrica Bonanni; Michelangelo Maestri; Gabriele Siciliano; Luigi Murri; Sara Gori
Journal:  Funct Neurol       Date:  2012 Apr-Jun

Review 9.  Treatment of restless legs syndrome.

Authors:  Cynthia L Comella
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

10.  Unaltered D1, D2, D4, and D5 dopamine receptor mRNA expression and distribution in the spinal cord of the D3 receptor knockout mouse.

Authors:  Hong Zhu; Stefan Clemens; Michael Sawchuk; Shawn Hochman
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2008-09-17       Impact factor: 1.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.